LSD-LIKE DELIRIUM FOLLOWING INGESTION OF A SMALL AMOUNT OF ITS BROM ANALOG (BOL-148)
Authors: N RICHARDS, L F CHAPMAN, H GOODELL, H G WOLFF
Journal: Annals of Internal Medicine (1958)

Case Reports1 May 1958LSD-LIKE DELIRIUM FOLLOWING INGESTION OF A SMALL AMOUNT OF ITS BROM ANALOG (BOL-148)NELSON RICHARDS, LORING F. CHAPMAN, HELEN GOODELL, HAROLD G. WOLFF, F.A.C.P.NELSON RICHARDSSearch for more papers by this author, LORING F. CHAPMANSearch for more papers by this author, HELEN GOODELLSearch for more papers by this author, HAROLD G. WOLFF, F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-48-5-1078 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn 1943 Hoffmann1 detected in himself strange mental effects from a compound that he and Stoll2 had prepared in 1938 and reported in 1943 as an oxytocic agent similar to ergonovine. This observation of the effect of lysergic acid diethylamide (LSD) led to the investigation of other derivatives of this compound in research on experimentally induced mental disorders.3 LSD and most of its related compounds have been found to produce an anti-5-hydroxytryptamine (serotonin) effect both peripherally and, it has been assumed, centrally by blocking the action of serotonin.3aCerletti and Rothlin4have reported on a compound, 2-bromo-d-lysergic acid diethylamide,...Bibliography1. Stoll WA: Lysergsaure-diathylamid, ein Phantasikum aus der Mutterkorngruppe, Schweiz. Arch. f. Neurol. u. Psychiat. 60: 279, 1947. Google Scholar2. StollHoffmann WAA: Partialsynthese von Alkaloiden vom Typus des Ergobasins (6. Mitteilung uber Mutterhornalkaloide), Helvet. chem. acta 26: 944, 1943. CrossrefGoogle Scholar3. Abramson HA editor: Neuropharmacology, Transactions of the Second Conference, May 25, 26, and 27, 1955, 1956, The Josiah Macy, Jr. Foundation, New York. (a) ibid. pages 47-82. (b) ibid. pages 236-258. Chapter on experimentally induced psychosis in man. (c) ibid. pages 9-84. Chapter on LSD and related compounds. (d) ibid. pages 29-30. (e) ibid. page 36. (f) ibid. page 33. (g) ibid. page 34. Google Scholar4. CerlettiRothlin AE: Role of 5-hydroxytryptamine in mental diseases and its antagonism to lysergic acid derivatives, Nature, London 176: 785-786 (Oct. 22) 1955. CrossrefMedlineGoogle Scholar5. GinzelMayer-Gross KHW: Prevention of psychological effects of d-lysergic acid diethylamide (LSD-25) by its 2-brom derivative (BOL-148), Nature, London 178: 210 (July 28) 1956. CrossrefMedlineGoogle Scholar6. AbramsonJarvikGorinHirsch HAMEMHMW: Lysergic acid diethylamide (LSD-25): tolerance development and its relationship to a theory of psychosis, J. Psychol. 41: 81, 1956. CrossrefGoogle Scholar7. IsbellFraserWiklerBelleville HHFARE: Tolerance to diethylamide of lysergic acid, Federation Proc. 14: 354, 1955. Google Scholar8. Savage C: Variations in ego feeling induced by d-lysergic acid diethylamide (LSD-25), Psychoanalyt. Rev. 42: 1, 1955. MedlineGoogle Scholar9. SnowLennard-JonesCurzonStacey PJJEGRS: Humoral effects of carcinoid tumours, Lancet 2: 1004, 1955. CrossrefGoogle Scholar10. BerlinGuthrieWeiderGoodellWolff LTAHHG: Studies in human cerebral function: the effects of mescaline and lysergic acid on cerebral processes pertinent to creative activity, J. Nerv. and Ment. Dis. 122: 487, 1955. CrossrefMedlineGoogle Scholar11. De Giacomo U: Les catatonies toxiques experimentales, Acta neurol. (Naples) 6: 5, 1951. Google Scholar12. DelayPichot JP: Diethylamide de l'acide d-lysergique et troubles psychiques de l'ergotisme, Compt. rend. Soc. d. biol. 145: 1609, 1951. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, N. Y.*Received for publication July 6, 1957.From the Study Program in Human Health and the Ecology of Man and the Departments of Medicine (Neurology) and Psychiatry, The New York Hospital-Cornell Medical Center.†Supported in part by a training grant from the National Institute of Neurological Diseases and Blindness.Requests for reprints should be addressed to Harold G. Wolff, M.D., The New York Hospital, 525 East Sixty-eighth Street, New York 21, N. Y. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byNeuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic PsychedelicsSerotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of ActionLicit and Illicit Drug Use in Cluster HeadacheIllicit drugs and cluster headache: An inevitable discussionIs BOL-148 hallucinogenic?Response to Tfelt-Hansen P: Is BOL-148 hallucinogenic?The effects of LSD and some analogues on the responses of single cortical neurons of the cat to optical stimulationSome Compounds With Hallucinogenic ActivityPharmacology and Classification of LSD-like HallucinogensEffects ofd-lysergic acid diethylamide and 2-brom-lysergic acid diethylamide on dominance behavior of the ratInhibition of Isolation-Induced Attack behavior of Mice by DrugsFactors Modifying Chlorpromazine Hyperthermia in Young Albino Mice 1 May 1958Volume 48, Issue 5Page: 1078-1083KeywordsDeliriumDepressionEcologyHypoxiaIngestionIntoxicationLysergic acid diethylamideNeurologyPsychosesSerotonin ePublished: 1 December 2008 Issue Published: 1 May 1958 PDF downloadLoading ...